ZBIO at a glance
Zenas BioPharma, Inc. (ZBIO, SEC CIK 1953926) filed its latest 10-K annual report on March 16, 2026, a 10-Q quarterly report on August 13, 2026, an 8-K current report on August 13, 2026 and Form 4 insider filings as recently as September 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Zenas BioPharma, Inc. (ZBIO) reported revenue of $10.0 million (up 100.0% from FY2024) and a net loss of $377.7 million. Diluted EPS was -$8.44.
- As of June 30, 2026, 23 institutional investment managers tracked by SignalX reported holding Zenas BioPharma, Inc. (ZBIO) shares worth $532.4 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $10.0M
- +100.0% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 23 funds
- $532.4M · +0 vs prior quarter
- Latest 8-K
- Aug 13, 2026
- Item 2.02 · Item 5.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- No product revenue; collaboration and license revenue included a $1.0M Tenacia milestone in June 2026
- Net loss $111.5M vs $52.2M YoY for the quarter
- Cash, equivalents and investments $673.9M at June 30, 2026
- ATM proceeds $71.5M; $96.8M remaining availability
- Outlook: funding expected into 2029, subject to potential $75M milestones and $75M Pharmakon borrowing
Risk Factors
- Newly added tariff risk triggered by April 2026 U.S. tariffs on patented pharmaceutical products
- China supply-chain exposure, including sole obexelimab CMO WuXi Biologics and orelabrutinib partner InnoCare
- Debt-servicing shortfall risk, with no foreseeable operating cash flow sufficient for indebtedness and capital expenditures
- Convertible Notes liquidity risk, requiring cash settlement upon certain conversions, maturity, or fundamental changes
- CFO transition risk, with Jennifer Fox departing September 30, 2026 and interim finance duties assigned to COO Joseph Farmer
AI summary of the ZBIO 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Section 2.02 text contains only a forward-incorporation disclaimer
- No fiscal-year 2026 operating results, financial figures, or performance metrics disclosed
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Christy J. Oliger appointed independent Class II director effective September 1, 2026, serving through the 2029 annual meeting
- Board expanded by one seat, increasing governance capacity and committee oversight
Item EX-99.1: Item EX-99.1
- FDA accepted obexelimab’s IgG4-RD BLA, with PDUFA action targeted for May 27, 2027, materially advancing potential commercialization
- Phase 3 INDIGO data showed 56% lower flare risk, with 73.2% flare-free versus 45.4% for placebo at Week 52
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Tomas Kiselak’s board term ended May 11, 2026, following his decision not to seek re-election
- Board size reduced by one, potentially affecting governance capacity and committee composition
Item 2.02: Results of Operations and Financial Condition
- Quarterly financial results released for period ended March 31, 2026
- Press release furnished as Exhibit 99.1, containing the substantive financial details
Item 5.07: Submission of Matters to a Vote of Security Holders
- James Boylan and Patrick Enright elected as Class II directors through the 2029 annual meeting
- Director votes included 4,458,184 broker non-votes, reflecting shares not counted on uncontested elections
AI summaries of ZBIO 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ZBIO
Don't miss the next ZBIO filing
- Alerts as it files. A push when ZBIO files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ZBIO, by share count.
- Ask anything. An AI agent that reads every ZBIO filing and answers with sources.
ZBIO alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Oliger Christy J. | A | Sep 1, 2026 | 37,000 | - |
| Allen Patricia L | A | Jun 15, 2026 | 18,500 | - |
| MOULDER LEON O JR | A | Jun 15, 2026 | 500,000 | - |
| Boylan James P | A | Jun 15, 2026 | 18,500 | - |
| Lu Hongbo | A | Jun 15, 2026 | 18,500 | - |
| Fox Jennifer A. | A | Jun 15, 2026 | 125,000 | - |
| ORLOFF JOHN J | A | Jun 15, 2026 | 18,500 | - |
| Farmer Joseph L | A | Jun 15, 2026 | 175,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $50.0M | $5.0M | $10.0M |
| Operating Income | - | -$163.9M | -$383.1M |
| Net Income | - | -$157.0M | -$377.7M |
| Op. Margin | - | -3277.8% | -3830.6% |
| Net Margin | - | -3139.8% | -3777.4% |
| Balance Sheet | |||
| Total Assets | $68.2M | $370.0M | $383.6M |
| Equity | -$225.7M | $312.5M | $242.1M |
| ROE | - | -50.2% | -156.0% |
| Per Share | |||
| EPS | $-24.25 | $-11.89 | $-8.44 |
| Cash Flow | |||
| Operating CF | - | -$119.7M | -$172.3M |
| CapEx | - | $131K | $18K |
Source: XBRL data in Zenas BioPharma, Inc. (ZBIO)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate ZBIO share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 23 | $532.4M |
| Q1 2026 | 23 | $324.8M |
| Q4 2025 | 20 | $460.6M |
| Q3 2025 | 18 | $189.5M |
| Q2 2025 | 17 | $66.6M |
| Q1 2025 | 12 | $34.6M |
| Q4 2024 | 12 | $28.5M |
| Q3 2024 | 6 | $4.9M |
- T. Rowe Price Group+869.7K (+243%)
- Bank of America Corp+842.8K (+217%)
- BlackRock+648.7K (+32%)
- State Street Corp+584.2K (+40%)
- Two Sigma Investments+540.1K (+196%)
- Goldman Sachs Group−110.3K (-29%)
- Invesco Ltd−94.5K (-83%)
- AQR Capital Management−19.9K (-39%)
- U.S. Bancorp−690 (-69%)
- JPMorgan Chase & Co−664 (-3%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 131 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ZBIO filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| SC 13G | Sep 8, 2026 | - | - | |
| 4 | Sep 2, 2026 | - | - | - |
| 10-Q | Aug 13, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 13, 2026 | - | Analysis | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 8-K | May 13, 2026 | - | Analysis | |
| 10-Q | May 13, 2026 | Mar 31, 2026 | Analysis | |
| SC 13D | May 5, 2026 | - | - | |
| 4 | Apr 29, 2026 | - | - | - |
| 4 | Apr 2, 2026 | - | - | - |
| 4 | Apr 1, 2026 | - | - | - |
| 4 | Mar 31, 2026 | - | - | - |
| 8-K | Mar 31, 2026 | - | - | - |
| 4 | Mar 31, 2026 | - | - | - |
| 10-K | Mar 16, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 16, 2026 | - | Analysis | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
ZBIO SEC filings: frequently asked questions
Which institutions hold ZBIO stock?
As of June 30, 2026, the largest Zenas BioPharma, Inc. (ZBIO) holders among the 13F filers tracked by SignalX were FMR LLC (Fidelity) ($241.3 million), BlackRock ($68.2 million), State Street Corp ($52.2 million), Vanguard Capital Management LLC ($34.4 million), Bank of America Corp ($31.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ZBIO's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Zenas BioPharma, Inc. (ZBIO) reported revenue of $10.0 million (up 100.0% from FY2024) and a net loss of $377.7 million. Diluted EPS was -$8.44. The figures come from the XBRL data in the 10-K.
What did ZBIO report in its latest 8-K?
Zenas BioPharma, Inc. (ZBIO) filed an 8-K on August 13, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 5.02 (Departure/Appointment of Directors or Principal Officers). Section 2.02 text contains only a forward-incorporation disclaimer.
What are the latest ZBIO SEC filings?
Zenas BioPharma, Inc. (ZBIO) filed its latest 10-K annual report on March 16, 2026, a 10-Q quarterly report on August 13, 2026, an 8-K current report on August 13, 2026 and a Form 4 insider filing on September 2, 2026.
What is ZBIO's SEC CIK number?
Zenas BioPharma, Inc. (ZBIO)'s SEC Central Index Key (CIK) is 1953926. EDGAR lists every ZBIO filing under that number.
Ask anything about ZBIO
The research agent reads ZBIO's filings, financials, insider trades and 13F holders, then answers with sources.